Mochinaga S - Search Results

1

Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer.

Mochinaga S, Okahashi T, Koga S, Nakano Y, Yakabe T, Sumi K, Kitahara K, Noshiro H, Kimura S, Fujito H. Mochinaga S, et al. Oncol Res. 2011;19(10-11):511-8. doi: 10.3727/096504011x13127606672887. Oncol Res. 2011. PMID: 22715594

2

Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients.

Miyahara T, Mochinaga S, Kimura S, Aragane N, Yakabe T, Morita S, Okudaira K, Fujito H. Miyahara T, et al. Among authors: mochinaga s. Cancer Chemother Pharmacol. 2013 Jan;71(1):175-82. doi: 10.1007/s00280-012-1994-8. Epub 2012 Oct 12. Cancer Chemother Pharmacol. 2013. PMID: 23064956

3

[Antiemetic effect of aprepitant in cancer patients receiving Cisplatin regimen].

Yakabe T, Mochinaga S, Fujito H, Noshiro H, Aragane N, Kimura S. Yakabe T, et al. Among authors: mochinaga s. Gan To Kagaku Ryoho. 2012 Jan;39(1):69-73. Gan To Kagaku Ryoho. 2012. PMID: 22241354 Clinical Trial. Japanese.

4

[Efficacy of aprepitant for quality of life of outpatients receiving moderately emetogenic chemotherapy].

Mochinaga S, Sumi S, Yakabe T, Aragane N, Noshiro H, Kimura S, Fujito H. Mochinaga S, et al. Gan To Kagaku Ryoho. 2012 Jun;39(6):933-7. Gan To Kagaku Ryoho. 2012. PMID: 22705688 Japanese.

5

A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.

Ureshino N, Aragane N, Nakamura T, Ide M, Mochinaga S, Fukushima N, Hayashi S, Sueoka E, Kimura S. Ureshino N, et al. Among authors: mochinaga s. Oncol Res. 2011;19(3-4):111-4. doi: 10.3727/096504011x12935427587687. Oncol Res. 2011. PMID: 21473286

6

Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.

Hosoya K, Mochinaga S, Emoto A, Yokoo H, Tokushima H, Egoshi M, Sueoka-Aragane N, Kimura S. Hosoya K, et al. Among authors: mochinaga s. Int J Clin Oncol. 2015 Dec;20(6):1203-10. doi: 10.1007/s10147-015-0843-2. Epub 2015 May 23. Int J Clin Oncol. 2015. PMID: 26002407

7

Safety of Long-term Use of Lamotrigine for the Treatment of Psychiatric Disorders.

Sogawa R, Mochinaga S, Inaba T, Matsushima J, Mizoguchi Y, Kawashima T, Fujito H, Monji A. Sogawa R, et al. Among authors: mochinaga s. Clin Neuropharmacol. 2016 Nov/Dec;39(6):295-298. doi: 10.1097/WNF.0000000000000174. Clin Neuropharmacol. 2016. PMID: 27438184

8

2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.

Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S. Yokoo M, et al. Among authors: mochinaga s. PLoS One. 2015 Nov 4;10(11):e0141946. doi: 10.1371/journal.pone.0141946. eCollection 2015. PLoS One. 2015. PMID: 26535909 Free PMC article.

9

Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer.

Nakafusa Y, Tanaka M, Ohtsuka T, Miyoshi A, Kohya N, Kitajima Y, Sato S, Mochinaga S, Dohi S, Miyazaki K. Nakafusa Y, et al. Among authors: mochinaga s. Mol Med Rep. 2008 Nov-Dec;1(6):925-30. doi: 10.3892/mmr_00000051. Mol Med Rep. 2008. PMID: 21479507

10

Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.

Matsuo M, Togawa M, Hirabaru K, Mochinaga S, Narita A, Adachi M, Egashira M, Irie T, Ohno K. Matsuo M, et al. Among authors: mochinaga s. Mol Genet Metab. 2013 Jan;108(1):76-81. doi: 10.1016/j.ymgme.2012.11.005. Epub 2012 Nov 15. Mol Genet Metab. 2013. PMID: 23218948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters